Acta Neuropathologica

, Volume 120, Issue 1, pp 13–20 | Cite as

Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease

  • Delphine Boche
  • Jane Donald
  • Seth Love
  • Scott Harris
  • James W. Neal
  • Clive Holmes
  • James A. R. Nicoll
Original Paper

Abstract

Alzheimer’s disease (AD) pathology is characterised by aggregation in the brain of amyloid-β (Aβ) peptide and hyperphosphorylated tau (phospho-tau), although how these proteins interact in disease pathogenesis is unclear. Aβ immunisation results in removal of Aβ from the brain but cognitive decline continues to progress, possibly due to persistent phospho-tau. We quantified phospho-tau and Aβ42 in the brains of 10 AD patients (iAD) who were actively immunised with Aβ42 (AN1792, Elan Pharmaceuticals) compared with 28 unimmunised AD cases (cAD). The phospho-tau load was lower in the iAD than the cAD group in the cerebral cortex (cAD 1.08% vs. iAD 0.72%, P = 0.048), CA1 hippocampus (cAD 2.26% vs. iAD 1.05%; P = 0.001), subiculum (cAD 1.60% vs. iAD 0.31%; P = 0.001) and entorhinal cortex (cAD 1.10% vs. iAD 0.18%; P < 0.001). Assessment of the localisation within neurons of phospho-tau indicated that the Aβ immunotherapy-associated reduction was confined to neuronal processes, i.e. neuropil threads and dystrophic neurites. However, the phospho-tau accumulation in the neuronal cell bodies, contributing to neurofibrillary tangles, appeared not to be affected. In showing that Aβ immunisation can influence phospho-tau pathology, we confirm the position of Aβ as a target for modifying tau accumulation in AD and demonstrate a link between these proteins. However, the continuing progression of cognitive decline in AD patients after Aβ immunisation may be explained by its lack of apparent effect on tangles.

Keywords

Alzheimer’s disease Tau Immunisation Amyloid 

References

  1. 1.
    Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115–9129CrossRefPubMedGoogle Scholar
  2. 2.
    Bayer AJ, Bullock R, Jones RW et al (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64:94–101PubMedGoogle Scholar
  3. 3.
    Berger Z, Roder H, Hanna A et al (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27:3650–3662CrossRefPubMedGoogle Scholar
  4. 4.
    Biernat J, Mandelkow EM, Schroter C et al (1992) The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 11:1593–1597PubMedGoogle Scholar
  5. 5.
    Boche D, Zotova E, Weller RO et al (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain 131:3299–3310CrossRefPubMedGoogle Scholar
  6. 6.
    Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 16:271–278 (discussion 278–284)CrossRefPubMedGoogle Scholar
  7. 7.
    Brendza RP, Bacskai BJ, Cirrito JR et al (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 115:428–433PubMedGoogle Scholar
  8. 8.
    Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol 14:11–20PubMedGoogle Scholar
  9. 9.
    Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 189:167–169CrossRefPubMedGoogle Scholar
  10. 10.
    Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185CrossRefPubMedGoogle Scholar
  11. 11.
    Holmes C, Boche D, Wilkinson D et al (2008) Long term effect of Abeta42 immunization in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223CrossRefPubMedGoogle Scholar
  12. 12.
    Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease from the National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. J Neuropathol Exp Neurol 56:1095–1097CrossRefPubMedGoogle Scholar
  13. 13.
    Johnson-Wood K, Lee M, Motter R et al (1997) Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 94:1550–1555CrossRefPubMedGoogle Scholar
  14. 14.
    Lowe J, Mirra SS, Hyman BT, Dickson DW (2008) Ageing and dementia. In: Love S, Louis DN, Ellison DW (eds) Greenfield’s neuropathology, 8th edn. Edward Arnold Ltd., London, pp 1031–1152Google Scholar
  15. 15.
    Masliah E, Hansen L, Adame A et al (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129–131PubMedGoogle Scholar
  16. 16.
    Mitchell TW, Nissanov J, Han LY et al (2000) Novel method to quantify neuropil threads in brains from elders with or without cognitive impairment. J Histochem Cytochem 48:1627–1638PubMedGoogle Scholar
  17. 17.
    Morgan D, Diamond DM, Gottschall PE et al (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408:982–985CrossRefPubMedGoogle Scholar
  18. 18.
    Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68:1–14CrossRefPubMedGoogle Scholar
  19. 19.
    Nicoll JA, Barton E, Boche D et al (2006) Abeta species removal after Abeta42 immunization. J Neuropathol Exp Neurol 65:1040–1048CrossRefPubMedGoogle Scholar
  20. 20.
    Nicoll JA, Wilkinson D, Holmes C et al (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448–452CrossRefPubMedGoogle Scholar
  21. 21.
    Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321–332CrossRefPubMedGoogle Scholar
  22. 22.
    Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177CrossRefPubMedGoogle Scholar
  23. 23.
    Serrano-Pozo A, Williams MW, Ferrer I et al (2010) Beneficial effect of human anti-Aβ active immunization on neurite morphology and tau pathology. Brain 133:1312–1327Google Scholar
  24. 24.
    Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer’s disease and related tauopathies. Curr Alzheimer Res 6:446–450CrossRefPubMedGoogle Scholar
  25. 25.
    Wilcock DM, Gharkholonarehe N, Van Nostrand WE et al (2009) Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer’s disease. J Neurosci 29:7957–7965CrossRefPubMedGoogle Scholar
  26. 26.
    Wittmann CW, Wszolek MF, Shulman JM et al (2001) Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293:711–714CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Delphine Boche
    • 1
  • Jane Donald
    • 1
  • Seth Love
    • 2
  • Scott Harris
    • 3
  • James W. Neal
    • 4
  • Clive Holmes
    • 1
    • 5
  • James A. R. Nicoll
    • 1
    • 6
  1. 1.Division of Clinical Neurosciences, School of Medicine, Southampton General HospitalUniversity of SouthamptonSouthamptonUK
  2. 2.Department of NeuropathologyUniversity of BristolBristolUK
  3. 3.Public Health Sciences and Medical Statistics FacultyUniversity of SouthamptonSouthamptonUK
  4. 4.Department of PathologyUniversity of WalesCardiffUK
  5. 5.M.A.R.C., Moorgreen HospitalHampshire Partnership FoundationSouthamptonUK
  6. 6.Department of Cellular PathologySouthampton University Hospitals NHS TrustSouthamptonUK

Personalised recommendations